Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.24
Bid: 2.18
Ask: 2.30
Change: -0.015 (-0.67%)
Spread: 0.12 (5.505%)
Open: 2.24
High: 2.24
Low: 2.24
Prev. Close: 2.255
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SABMiller exec buys a round

Tue, 24th Jan 2012 16:32

The Managing Director of SABMiller's African division bought a round of shares just one day before the drinks giant announced it has signed a definitive transaction agreement with Anadolu Group and Anadolu Efes.The agreement allows the firm to form a strategic alliance between the firm's divisions in Turkey, Russia, the Commonwealth of Independent States (CIS), Central Asia and the Middle East. The terms of the agreement, announced back in October, mean that SABMiller will now transfer its Russian and Ukranian beer divisions (valued at $1.9bn) to Anadolu Efes, the fifth-largest European brewer and the world's sixth-largest Coca-Cola bottler. In return, SABMiller will hold a 24% equity stake in Andolu Efes. Mark Bowman, 45, purchased 963 shares at 2,382.845p each. Just a few days ago the brewer reported that its financial performance for the final quarter of 2011 had been in line with expectations. However, the European and North American divisions were noticeably weak, with larger volumes in Europe falling 2% while in the US sales were down 3.3%. Top Director BuysImmupharma (IMM) Director name: Mr Ajay AgrawalAmount purchased: 62,169 @ 80.00p Value: £49,735Immupharma (IMM) Director name: Dr Franco Di MuzioAmount purchased: 60,950 @ 81.00p Value: £49,370Stobart Group Ltd. (STOB) Director name: Mr Jesper KjaedegaardAmount purchased: 22,000 @ 122.80p Value: £27,016Mission Marketing Group (TMMG) Director name: Mr Dylan BoggAmount purchased: 100,000 @ 15.12p Value: £15,120Mediterranean Oil & Gas (MOG) Director name: Mr Miles DonnellyAmount purchased: 225,000 @ 5.30p Value: £11,925NR
More News
6 Feb 2020 15:54

ImmuPharma and Avion to proceed with Lupuzor phase 3 trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its activities with Avion Pharmaceuticals on Thursday, following the licence and development agreement it signed with Avion in November for the exclusive rights to 'Lupuzor' in North America.

Read more
13 Dec 2019 12:12

ImmuPharma To List On Life Sciences Heavy Brussels Index

ImmuPharma To List On Life Sciences Heavy Brussels Index

Read more
11 Dec 2019 14:54

ImmuPharma says not looking to raise funds

(Sharecast News) - AIM-listed specialist drug discovery and development company ImmuPharma insisted on Wednesday that it is not looking to raise funds.

Read more
11 Dec 2019 14:03

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

ImmuPharma Confirms It Will Not Raise Funds Despite Share Price Rise

Read more
28 Nov 2019 16:26

ImmuPharma shares soar as it teams up with Avion on Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced a licence and development agreement with Avion Pharmaceuticals on Thursday, for the exclusive rights to 'Lupuzor' in the United States.

Read more
28 Nov 2019 12:02

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Immupharma Shares Take Off On Lupuzor US Licencing Deal With Avion

Read more
28 Nov 2019 07:28

ImmuPharma licenses lupus drug Lupuzor to Avion in the United States

LONDON, Nov 28 (Reuters) - British pharmaceutical firm ImmuPharma said on Thursday it had signed a licensing and development agreement for Lupuzor, a first-in-class treatment for auto-immune disease Lupus, with U.S. company Avion Pharmaceuticals....

Read more
30 Sep 2019 10:40

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

ImmuPharma Loss Narrows Slightly, Focus On Lupuzor Regulatory Approval

Read more
28 Jun 2019 12:01

Immupharma Study Demonstrates Robust Safety Profile Of Lupuzor

(Alliance News) - Immupharma PLC on Friday reported analysis of the results from the study of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, a potentially life drug

Read more
28 Jun 2019 10:27

ImmuPharma pleased with Lupuzor open-label study results

(Sharecast News) - Specialist drug discovery and development company ImmuPharma released the analysis of results from the open-label six month extension study from its original pivotal phase 3 trial of 'Lupuzor' on Friday.

Read more
26 Jun 2019 11:15

Immupharma raises ?2.66m from subscription agreement with institutional investor

(Sharecast News) - Drug discovery and development specialist Immupharma raised roughly £2.66m via a subscription agreement with institutional investor Lanstead Capital on Wednesday.

Read more
26 Jun 2019 10:14

Immupharma Raises GBP2.7 Million From Share Subscription With Lanstead

(Alliance News) - Immupharma PLC on Wednesday announced a 26.6 million share subscription to raise around GBP2.7 million at a price of 10 pence per share.The drug discovery and development

Read more
24 May 2019 11:47

Immupharma 2018 Loss Widens Amid Placing; Progresses On Pipeline

LONDON (Alliance News) - Drug development firm Immupharma PLC said Friday its 2018 loss widened amid share placing costs, whilst it continued to make "key" progress in its 2018, pretax a

Read more
7 May 2019 11:06

ImmuPharma Exploring European Listing For Combined French Businesses (ALLIPO)

LONDON (Alliance News) - ImmuPharma PLC is exploring the merger and possible separate listing of two French subsidiaries, it said Tuesday.Elro Pharma Sarl and Ureka Sarl are currently on a

Read more
1 Apr 2019 14:07

ImmuPharma Loses Exclusivity Period For Talks With Incanthera

LONDON (Alliance News) - ImmuPharma PLC on Monday said proposed partner Incanthera Ltd can now talk with other potential parties after an exclusivity period ended.In September, ImmuPharma a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.